Pfizer Guideline Concordant Care and Emerging Data for Patients with Muscle Invasive Bladder Cancer (MIBC) through locally advanced or metastatic Urothelial Carcinoma (la/mUC)

This competitive program seeks to bring awareness and knowledge to healthcare professionals regarding the current gaps in the rapidly evolving bladder cancer treatment landscape, focused on existing and emerging data to optimize treatment for patients with MIBC and locally advanced or metastatic urothelial carcinoma (la/mUC).